Back to Awarded Treatment Trials
Awarded Trial: 02T-271
Grant ID
02T-271
Illness
Schizophrenia
Primary Drug/Intervention
Rosiglitazone
Primary Dosage
4 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Henderson
Sample Size
40
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
Glucose tolerance, insulin level, cognitive battery
Results
Thirty-four patients were randomized and 20 completed the study. Patients receiving rosiglitazone experienced a significant improvement in effectiveness of glucose utilization and insulin sensitivity. There was no beneficial effect on cognition.
Publication
Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand. 2009 Jun;119(6):457-65. Yi Z1, Fan X, Wang J, Liu D, Freudenreich O, Goff D, Henderson DC. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res. 2012 Dec 30;200(2-3):79-82.
Link
http://www.ncbi.nlm.nih.gov/pubmed/19183127; http://www.ncbi.nlm.nih.gov/pubmed/22727707
PI Name
David Henderson
Degree
MD
Center
Freedom Trail Clinic
Institution
Massachusetts General Hospital, Harvard Medical School
Address
25 Staniford Street
City or Town
Boston
State or Province
MA
Zip or Postal Code
2114
Country
USA
Email Address
dchenderson@partners.org